Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ADMA Biologics Inc (ADMA) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Biologics Inc (ADMA) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 31st
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:
ADMA Biologics, Inc. (ADMA - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
ADMA Biologics Inc Price and Consensus
ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote
ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
ADMA Biologics Inc Price
ADMA Biologics Inc price | ADMA Biologics Inc Quote
Ekso Bionics Holdings, Inc. (EKSO - Free Report) : This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.
Ekso Bionics Holdings, Inc. Price and Consensus
Ekso Bionics Holdings, Inc. price-consensus-chart | Ekso Bionics Holdings, Inc. Quote
Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
Ekso Bionics Holdings, Inc. Price
Ekso Bionics Holdings, Inc. price | Ekso Bionics Holdings, Inc. Quote
InhibikaseTherapeutics, Inc. (IKT - Free Report) : This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.